Ampicillin
Brand names: Penbritin
Ampicillin is a broad-spectrum aminopenicillin antibiotic used for susceptible infections including certain respiratory, urinary, gastrointestinal and listerial infections.
Adult dose
Paediatric dose
Dose adjustments
eMC §4.2, verbatim: 'In the presence of severe renal impairment (creatinine clearance 10ml/min) a reduction in dose or extension of dose interval should be considered. In cases of dialysis, an additional dose should be administered after the procedure.' The comparator symbol before '10ml/min' is missing from the fetched text (it reads as a bare '10ml/min'), so read the threshold from the SPC itself before applying it. No numeric replacement regimen is given. §4.4 repeats that 'Dosage should be adjusted in patients with renal impairment'. The creatinine-clearance dosing table in the US source belongs to ampicillin WITH sulbactam and has not been carried over.
No hepatic dose adjustment is given in this bundle. eMC §4.8 records that, as with other beta-lactam antibiotics, hepatitis and cholestatic jaundice have been reported rarely and a moderate and transient increase in transaminases has been reported. (The US contraindication for previous cholestatic jaundice/hepatic dysfunction relates to ampicillin with sulbactam, a different product.)
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
eMC §4.2, verbatim: 'Children dosage: 150 mg/kg daily IV in divided doses.' This figure sits in the MENINGITIS row of the SPC's dose table and should be treated as the meningitis dose rather than a general paediatric dose - see the table-flattening caveat in the adult notes. For routine (non-meningitis) paediatric dosing the SPC gives a fraction rule, not a per-kg rule: 'Half adult routine dosage for children under 10 years' - which cannot be expressed as a per-kg figure and so is recorded here only. No neonatal dose, no number of divided doses per day, no dose interval and no paediatric maximum are given anywhere in this bundle, and no age band is attached to the 150 mg/kg/day figure. CONCENTRATION: 50 mg/mL is the intravenous reconstitution from the SPC method of administration ('Dissolve 500 mg in 10 ml water for injections'); the intramuscular reconstitution is different (add 1.5 ml water for injections to a 500 mg vial), so this concentration applies to the IV route only. The US source in this bundle is ampicillin WITH SULBACTAM and its 300 mg/kg/day paediatric figure is a combination total (200 mg ampicillin plus 100 mg sulbactam per kg per day) - it has not been used here. Verify the paediatric dose, the dosing interval and any neonatal dose against a children's formulary.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients (eMC §4.3)
- History of hypersensitivity to beta-lactam antibiotics - e.g. ampicillin, penicillins, cephalosporins (eMC §4.3)
- Avoid if infectious mononucleosis and/or acute or chronic leukaemia of lymphoid origin are suspected, because of the associated skin rash (eMC §4.4 - a special warning rather than an absolute §4.3 contraindication)
Side effects
- Hypersensitivity: skin rash, pruritus and urticaria reported occasionally, with a higher incidence in infectious mononucleosis and acute or chronic leukaemia of lymphoid origin; purpura also reported. 'If any hypersensitivity reaction occurs, the treatment should be discontinued' (eMC §4.8)
- Rarely: erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis; anaphylaxis reported rarely (eMC §4.8, §4.4)
- Gastrointestinal: nausea, vomiting and diarrhoea; pseudomembranous colitis and haemorrhagic colitis reported rarely (eMC §4.8)
- Renal: interstitial nephritis can occur rarely (eMC §4.8)
- Hepatic: hepatitis and cholestatic jaundice reported rarely; moderate and transient increase in transaminases (eMC §4.8)
- Haematological: transient leucopenia, transient thrombocytopenia and haemolytic anaemia reported rarely; prolongation of bleeding time and prothrombin time also reported rarely (eMC §4.8)
- Injection-site reactions reported for the related combination product (ampicillin with sulbactam, US label, quoted for context only): pain at IM injection site 16%, pain at IV injection site 3%, thrombophlebitis 3%, phlebitis 1.2%
Monitoring
- Before starting: 'careful enquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics' (eMC §4.4)
- Watch for hypersensitivity and anaphylaxis - serious and occasionally fatal reactions have been reported with beta-lactams, more frequently following parenteral therapy (eMC §4.4)
- Renal function - dosage should be adjusted in renal impairment, with an additional dose after dialysis (eMC §4.2, §4.4)
- Prolonged use may occasionally result in overgrowth of non-susceptible organisms (eMC §4.4)
- Watch for diarrhoea - pseudomembranous colitis and haemorrhagic colitis have been reported rarely (eMC §4.8)
- Urine glucose testing: use enzymatic glucose oxidase methods, because high urinary ampicillin concentrations make false positive readings common with chemical methods (eMC §4.5)
- Sodium load in patients on a controlled sodium diet: 33.7 mg of sodium per vial (eMC §4.4)
- Do not mix with an aminoglycoside in the syringe, intravenous fluid container or giving set - loss of aminoglycoside activity can occur (eMC §4.5)
Clinical monograph
How it works
It inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, leading to bacterial lysis.
Prescribing in practice
- It is contraindicated in patients with penicillin hypersensitivity, who are at risk of anaphylaxis.
- A maculopapular rash is common if given in glandular fever (infectious mononucleosis) and it should be avoided in this setting.
- Many common organisms produce beta-lactamases conferring resistance, so therapy should be guided by susceptibility where possible.
Monitoring
Monitor for hypersensitivity reactions and clinical response, and review renal and hepatic function with prolonged or high-exposure treatment.
Counselling the patient
- Report any rash, swelling or breathing difficulty, which may indicate allergy.
- Complete the full prescribed course even if you feel better.
- Tell your prescriber if you have ever reacted to a penicillin.
Evidence & guidelines
Ampicillin and related aminopenicillins are long-established agents with well-defined roles in UK antimicrobial guidance.
Reference: BSAC Endocarditis Guidelines (2012 updated); NICE NG51 (Meningitis); PHE/UKHSA antibiotic guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Acute Otitis Media — Antibiotic or Observation (AAP 2013) · Otitis Media
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Diagnosis and Hospitalisation (CDC Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023